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Abstract
In controlled clinical trials, each of several prognostic factors should be balanced across the trial arms.
Traditional restricted randomization may be proved inadequate especially with small sample sizes. In
psychiatric disorders such as obsessive compulsive disorder (OCD), small trials prevail. Therefore, proce-
dures to minimize the chance of imbalance between treatment arms are advisable. This paper describes
a minimization procedure specifically designed for a clinical trial that evaluates treatment efficacy for
OCD patients. Aitchison’s compositional distance was used to calculate vectors for each possibility of
allocation in a covariate adaptive method. Two different procedures were designed to allocate patients in
small blocks or sequentially one-by-one. Partial results of this allocation procedure as well as simulated
ones are shown. In the clinical trial for which this procedure was developed, the balancing between
treatment arms was achieved successfully. Simulations of results considering different arrival order of
patients showed that most of the patients are allocated in a different treatment arm if arrival order is
modified. Results show that a random factor is maintained with the random arrival order of patients.
This specific procedure allows the use of a large number of prognostic factors for the allocation decision
and was proved adequate for a psychiatric trial design.
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1. INTRODUCTION
For some specific psychiatric disorders, large trials are fairly rare. Obsessive-compulsive disorder (OCD)
treatment, for instance, has only been studied in small trials. First-line treatments such as clomipramine
and selective serotonin reuptake inhibitors are typically studied in trials with no more than two hundred
patients (Eddy et al. 2004). For second-line treatments, such as pharmacological augmentation strategies,
the situation is worse, albeit understandably so (Bloch et al. 2006; Fontenelle et al. 2007). To our knowledge,
there have been no trials involving more than one hundred patients. Indeed, most such studies have presented
final sample sizes of no more than 15 patients per arm (Bloch et al. 2006).This is in stark contrast to what
is seen for studies of common clinical diseases such as hypertension and diabetes. Therefore, specific aspects
need to be taken into consideration when implementing clinical trials involving psychiatric patients, especially
those with OCD.
In small trials, such as those typically designed to study psychiatric disorders, an imbalance between
treatment arms, in terms of prognostic factors, can affect the interpretation of the results. One of the first
methods created to address this problem was stratified allocation of individuals (Lachin 1988).The use of this
method also reduces the need to adjust statistical data analysis for covariates that work as prognostic factors.
The limitation of stratified allocation is that it can only be applied when a small number of covariates are
involved. Otherwise, the sample has to be divided into a great number of strata with only a few patients in
each (Kernan et al. 1999). To overcome this limitation, it became necessary to devise alternative methods
of minimising imbalance among treatment arms.
Pocock and Simon (1975) devised a general procedure for treatment assignment that minimises imbalance
among the individual prognostic factors with a logistic similar to that employed to guide the procedure
subsequently described. Independently, Taves (1974) also developed a minimisation procedure that will not
be discussed in this article, as it is encompassed by the Pocock and Simon method.
Since 1975, various other authors have developed procedures to minimise the chance of imbalance be-
tween arms, as previously reviewed (Scott et al. 2002; Pocock et al. 2002). Each method has its specific
limitations and complexities. For example, the optimal design technique of allocation allowed the use of
continuous variables in their non-categorical format as covariates (Atkinson 1982). However, its complexity
and difficulty impeded its practical implementation. This example illustrates that no allocation procedure
is ideal. Therefore, novel methods are still required in specific situations.
In response to the need for specifically designed minimisation procedures in clinical trials involving in-
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dividuals with OCD, we developed an allocation method that uses the Aitchson distance (Aitchison 1983,
1986; Aitchison and Egozcue 2005) for compositional data. The Aitchson distance was chosen because all
prognostic factors used are disposed as categorical data with relative frequencies.
Here, we present the results of allocation of the partial sample collected during the first year of the study
for which this procedure was developed, as well as those of simulated samples that varied in terms of the
order of patient inclusion.
2. METHODS
2.1 Allocation
For clarity, let us consider the simplest design. Consider a clinical trial in which patients are enrolled
sequentially, according to the order in which they enter treatment at the clinic. Each patient is to be assigned
to one, and only one, of the two alternative treatments. Imagine that a new patient arrives after the study
already has a considerable number of patients under study in each of the two arms: n1 and n2. In addition,
consider that age, denoted by a, is a factor that we think should be adjusted for. Possible ages are divided
into three different categories: A1 if a < 30; A2 if 30 < a < 45; and A3 if a > 45. Consider now the following
notation:
1. Represent the sample absolute frequencies of n1 and n2, respectively, as (n11, n12, n13) and (n21, n22, n23),
i.e., for i = 1 or 2 and j = 1, 2 or 3, nij is the number of patients of age group Aj in arm i.
2. Represent the compositional vectors (the relative frequency vectors), respectively, asA1 = (A11, A12, A13)
and A2 = (A21, A22, A23), i.e., A22 = nij/ni is the relative frequency of patients in age group Aj in
arm i - proportion of age group Aj in arm i.
The allocation of a new incoming patient consists of the following steps:
i. Include the new patient in the first arm, represent the new composition vector as (A1)∗, and calculate
a distance between (A1)∗ and A2, i.e., evaluate the distance d1 = ∆[(A1)∗;A2].
ii. Include the new patient in the second arm, represents now the new compositional vector by (A2)∗, and
compute the distance d2 = ∆[A1; (A2)∗].
iii. Compare the values of d1 and d2. If d1 < d2, allocate the new patient to n1; if d1 > d2, allocate the
patient to n2; and if d1 = d2, the patient can be allocated to either arm.
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Note that we make our decision based on the values of the distances between the compositional vectors.
By compositional vectors, we understand vectors in which the sum of their components are fixed and known.
In our case, as we have relative frequencies, the values of the components are numbers in the interval [0; 1],
and the sum of these components is one. Aitchson (1983, 1986) argued that, for compositional data as such,
the correct distance measure is not the usual standard Euclidian measure but the one described below.
For some generalities, consider factor a having k (> 1) possible alternatives, in the place of the three
considered above, i.e., Ai = (Ai1, Ai2, . . . , Aik) is the relative frequency vector of arm i (= 1, 2). For category
j, consider the natural logarithm of the between-arm relative frequency ratio, rj = (A1j/A2j), denoted by
ln(rj), and the mean of these logarithms, denoted by L:
ln(rj) = ln(A1j)− ln(A2j)
and
L =
ln(r1) + ln(r2) + . . . + ln(rk)
k
The Aitchison distance measure between the two compositional vectors A1 and A2 is defined as follows:
∆[a1, a2] =
√√√√ k∑
j=1
(
ln(rj)− L
)2
To exemplify the use of the allocation procedure, let us consider the case of the three aging categories A1,
A2, and A3, as before. Suppose that, in one stage of the process, we had the following vectors of absolute
frequencies: n1 = (3; 7; 5) and n2 = (5; 6; 6). A new patient enrols and is in age category A2. Table 1 presents
the vectors for the calculus of the distances.
Table 1. Vectors of relative frequencies.
Aging A1 A2 A∗1 A
∗
2
A1 0.2000 0.2941 0.1875 0.2778
A2 0.4667 0.3529 0.5000 0.3889
A3 0.3333 0.3529 0.3125 0.3333
Sum 1 1 1 1
The following three expressions represent the intragroup distances, (not) including the new patient:
A. Before the new patient, ∆[A1;A2] = 0.4702
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B. With the new patient in n1, ∆[(A1)∗;A2] = 0.5676
C. With the new patient in n2, ∆[A1; (A2)∗] = 0.3661
The figures above indicate that the best allocation for a new patient that belongs to age category A2 is to
n2. This conclusion might appear obvious to the decision maker, as it is desirable to increase the frequency of
A2 in n2. Note that this choice increases the sample size of n2. It would be interesting if we could also control
the arm sample sizes. Let us also transform the sample size (s) into a compositional factor. Let us consider
the vectors s1 = (n1;n2)/n and s2 = (n2;n1)/n as the relative frequencies for n1 and n2, respectively. In our
example we would have the following:
s1 =
1
32
(15; 17) = (.47; .53), s2 = (.53; .47),
(s1)∗ = (.48; .52) and (s2)∗ = (.55; .45)
Here the ∗ indicates that the new patient entered a specific arm. The new distance values are ∆[s1; s2] = 0.1770,
∆[(s1)∗; s2] = 0.1314, and ∆[s1; (s2)∗] = 0.2174. Clearly, the best allocation would be to the first arm, which
has a smaller sample size. Bear in mind that, using age categories, our best choice would have been to
allocate the new patient to the second arm. However, the sample size factor indicates that the first arm is
the appropriate allocation for the new patient. If the decision maker feels that age is more important than
sample size, a larger weight could be given to age than to sample size. For example, consider that we decide
to use a weight of 2 for age and a weight of 1 for sample size. We could use the weighting average of the
distances to facilitate the decision. The results for our example are as follows:
i. new patient in n1 produces D1 =
2∆[(A1)∗;A2] + ∆[(s1)∗; s2]
3
= 0.4222
ii. new patient in n2 produces D2 =
2∆[A1; (A2)∗] + ∆[s1; (s2)∗]
3
= 0.3165
The overall distance using the two factors indicates that the new patient should be allocated to n2 in
order to make the arms closer in terms of age and sample size. It is also possible to give equal weights to the
two factors. Another point that could be questioned is the constructed factor for sample size. Note that, for
comparing factors, we need to have the same range for all factor distance measures. Hence, the definitions
of s1 and s2 seem to be quite adequate.
The examples discussed below are more specific and have interesting particularities. The first, related
to phase one of the trial described below, deals with two arms, four prognostic factors, and simultaneous
5
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
08
.2
10
2.
1 
: P
os
te
d 
21
 J
ul
 2
00
8
allocation of three patients each time. The second example, related to phase two, deals with seven prognostic
factors and one-by-one allocation of patients into three groups.
2.2 Two-phase clinical trial
A study group specialising in OCD delineated a clinical trial that consists of two phases. The objective
of phase one is to compare patient responses to pharmacological and psychotherapeutic treatments. There is
an expectation of 360 OCD patients to be enrolled in phase one over a 3-year period. However, for logistical
reasons, there is no expectation that the numbers of patients allocated to the individual treatment arms will
be similar in phase one. There will be times when the pharmacological arm receives more patients than does
the psychotherapeutic arm and other times when this relationship is reversed. These changes are necessary
because for pragmatic reasons each therapeutic arm accommodates a different number of patients in each
moment of the study. As the psychotherapeutic arm involves group psychotherapy, at moments when groups
are being initiated a fast inclusion of patients is necessary, but when groups have already been initiated the
speed of inclusion need to be diminish as only two groups can be conducted simultaneously.
From previous experience, it is expected that 60% of the patients treated in either of the two arms of phase
one will report less than adequate symptom improvement. Patients that participated in the pharmacological
arm (n1) and did not respond to treatment will be invited to participate in phase two. Patients who
are non-responders in the psychotherapeutic arm (n2) of phase one will be invited to participate in the
pharmacological arm (n1), and, if they maintain their treatment resistance in n1, they also will be invited
to participate in phase two. Phase two consists of three arms, the objective being to compare three different
pharmacological augmentation strategies. In phase two, unlike in phase one, it is expected that a similar
number of patients will be allocated to each of the three arms. Considering expected response rates, drop-out
rates, and frequency of refusals to participate in a study using a placebo, it is likely that 30 to 40 patients
will be included in each arm. This sample size seems to be adequate according to the investigator hypothesis.
The entire clinical trial design is illustrated in Figure 1.
The allocation strategies for the two phases of the trial are different. To accommodate the logistic
characteristics of phase one (that require a different pace of patient enrolment for each arm and at different
study time points), the designer will receive groups of 3 patients to be allocated into the two groups. On some
occasions, it might be necessary to allocate 2 patients to n1 and 1 to n2. On other, well-defined occasions,
the situation is reversed, n1 will receive 1 patient, and the other 2 patients will be allocated to n2.
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2.2.1 Prognostic factors to be balanced across arms
When the program for allocation was developed for phase one, a smaller number of variables to be adjusted
for was chosen, as we did not know how many covariates this new procedure could accommodate without
compromising its efficacy in minimising arm imbalance. After the first results of allocation were analysed for
phase one, it became clear that the procedure could accommodate a greater number of covariates. Therefore,
the program designed for phase two was created with a greater number of hypothesised prognostic factors
that could also have been covariates in phase one. The factors used to establish the allocating strategy were
chosen based on previous studies. Although the appropriateness of the factors used might be obvious, it is
not our intention to discuss this matter in this paper, the sole intention of which is to present the allocation
strategy used in the study described. The factors and their categories were as follows:
1. Current age was categorised into three classes: under 30 years of age (A0); between 31 and 45 (A1);
and over 45 (A2).
2. OCD symptom severity, as measured using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS),
was categorised as being in one of eight classes based on ordered scores for each of the two symptom
types (obsession and compulsion): ≤ 8 = low (L); 8-15 = moderate (M); and > 15 = high (H).
Therefore, the eight possible classes were as follows: (L;L), (L;M), (L;H), (M ;L), (M ;M), (M ;H),
(H;L), (H;M), and (H;H). The first and second notations are based on the scores for obsession and
compulsion, respectively. Clearly, (L;L) is not considered, as it would indicate no OCD symptoms,
and we had no patients in this class.
3. Treatment history was divided into three categories in each phase. In phase one, h0 indicates no
previous appropriate treatment, h1 indicates one previous course of appropriate treatment without
response, and h2 indicates two or more previous courses of appropriate treatment without response.
In phase two, h0 indicates no Y-BOCS score reduction or Y-BOCS score increase after n1 in phase
one, h1 indicates a 1-20% reduction in Y-BOCS score after n1 in phase one, and h2 indicates a 20-35%
reduction in Y-BOCS score after n1 in phase one.
4. Level of education was divided into four categories: sc0 indicates no schooling, sc1 indicates ≤ 8 years
of schooling, sc2 indicates 9-12 years of schooling, and sc3 indicates higher education (undergraduate
or graduate work).
5. Marital status was categorized as si0 (married, divorced or widowed) or si1 (single).
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6. Genders are indicated by m for male and f for female.
7. Sample sizes are denoted as n1, n2, n3, and n = n1 + n2 + n3, respectively, and by the total sample
size. Note that there are three arms only in phase two. The compositional view of sample size in arm
i (i = 1, 2, 3) is the vector (si; 1− si) where si = ni/n.
For each of these factors, the distance between arms can be computed. The distance values for the seven
variables listed above are given by the following symbols: ∆age, ∆OCD, ∆his, ∆sch, ∆mar, ∆gen, and ∆sam.
The global distances for phases one and two are, respectively, ∆1 and ∆2, defined as follows:
∆1 =
1
9
(
2∆age + 3∆OCD + 3∆his + ∆gen
)
∆2 =
1
21
(
2∆age + 4∆OCD + 5∆his + 2∆sch
+3∆mar + ∆gen + 4∆sam
)
As there are three arms in phase two, there are also three vectors. Hence the global distance for phase two
should be the average of the three values of ∆2, i.e., the distance for phase two should be as follows:
∆2 =
∆2(n1;n2) + ∆2(n1;n3) + ∆2(n2;n3)
3
2.2.2 Phase one allocation strategy
To allocate the patients into the two arms of phase one based on previous studies, it is desirable that
some prognostic factors be distributed as homogeneously as possible between the two arms. It is assumed
that previous treatment response (assessed through patient interviews) and severity of the disorder (assessed
using a specific scale) at the time of inclusion in the study are the most important prognostic factors for
clinical response. In addition, although of lesser importance to treatment response, gender and age should
also present homogeneous distribution between arms. For logistical reasons, the number of patients enrolled
in each treatment arm of phase one could not be the same: the professionals involved in providing treatment
are able to assist more patients in the pharmacological arm than in the psychotherapeutic arm; and, over the
course of the study, there are moments at which the pace of patient enrolment into the psychotherapeutic
arm is, of necessity, more rapid than is that of patient enrolment into the pharmacological arm. It is expected
that the pharmacological arm will account for a higher percentage of the final sample. Due the time needed
to perform the clinical evaluations, there is a two-week gap between inclusion and allocation. Consequently,
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it is possible to allocate patients simultaneously in groups of three, one to one arm and the remaining two
to the other arm (the arm that receives two patients in some steps receiving one in other steps). This
simultaneous inclusion of patients guarantees that blinding is not compromised by allocation in small blocks.
The choice of prognostic factors to be balanced between arms is based on reports in the literature
indicating that prognostic factors have considerable influence on the results. In addition, having information
on these factors at the time of the initial evaluation can inform these choices. As previous treatment
response and initial severity are consistently reported to be associated with treatment response in clinical
trials evaluating OCD patients (De Haan et al. 1987, Alarcon et al. 1993, Thompsen and Mikkelsen 1995,
Mataix-Cols et al. 1999; Steketee et al. 1999), they were included as prognostic factors in order to balance
the arms.
2.2.3 Phase two allocation strategy
Patients entering phase two were those that did not completely respond to the treatment in n1 of phase one
(regardless of treatment history). The specialists assumed that treatment response and current severity were
highly predictive of phase two treatment response, and that these patients should therefore be distributed
homogeneously among the three groups. In addition, it is understood from previous studies that level of
education and marital status are significantly associated with poor treatment response and should also be
included in the phase two strategy model. Gender and current age should also be distributed homogeneously
among the three arms. Another important factor is sample size, which should be as similar as possible among
the three arms.
For each patient in phase two, the allocation to one of the three arms needs to be determined during
the evaluation conducted at week 12 of treatment. The strategy at this point is sequential, one-by-one
allocation of patients who had participated in phase one. Here, in addition to having more than two factors
to consider in our attempts to balance the arms, we are dealing with three arms. Bear in mind that the
distance measures are defined for two vectors in order to facilitate decisions regarding patient allocation, we
consider the average of the three distances between pairs to be the overall distance of the three arms. The
proposed solutions for the two phases are described below.
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3. RESULTS
3.1 Partial results for phase one
To perform stratified allocation of patients, an Excel macro was created. The objective of this macro was
to divide patients into homogenous subgroups of intervention regarding the factors chosen by investigators.
To avoid empty categories in the allocation process, for a factor with k (> 1) categories, we added to each
category the fraction 1/k. Therefore no category had a frequency of 0 at the time of the calculation of the
∆ distance. When the optimal allocation process began, 34 patients had already been randomly allocated
to one or the other of the two arms.
The partition that provides the best degree of homogeneity between groups is defined as the division
that achieved the smaller difference between factor vectors of category relative frequencies. To calculate this
measure, the Aitchison distance between two vectors is used, as previously discussed. This distance was
chosen based on the assumption that it has the property of preserving the sub-compositional coherence of
the simplex space. After the values of ∆1 are calculated for each possible allocation, the allocation that
results in the least intragroup distance is chosen as the optimal allocation.
At this writing, 92 individuals had been allocated to n1, and 77 had been allocated to n2. The partial
allocation exercise, considering these patients, is shown in Table 2. The results of the reverse order allocation
of patients appear within parentheses in the same Table.
Table 2. Partial (reverse order) allocation of 169 patients in phase one.
Prognostic Compositional Arm 1 frequencies Arm 2 frequencies
factor category Absolute Relative Absolute Relative
Current A0 45 (45) 0.489 38 (38) 0.494
age A1 33 (32) 0.359 27 (27) 0.351
A2 14 (15) 0.152 12 (12) 0.156
OCD (L;M) 1 (1) 0.011 1 (1) 0.013
symptom (M;L) 2 (1) 0.022 1 (2) 0.013
severity (L;H) 2 (2) 0.022 2 (2) 0.026
(H;L) 3 (2) 0.033 0 (1) 0.000
(M;M) 35 (36) 0.380 32 (31) 0.416
(M;H) 10 (11) 0.109 9 (8) 0.117
(H;M) 9 (10) 0.098 9 (8) 0.117
(H;H) 30 (29) 0.326 23 (24) 0.299
Treatment h0 49 (51) 0.533 43 (41) 0.558
history h1 8 (0) 0.087 2 (0) 0.026
h2 35 (41) 0.380 32 (36) 0.416
Gender m 40 (40) 0.435 34 (34) 0.442
f 52 (52) 0.565 43 (43) 0.558
Sample Arm size 92 0.544 77 0.456
size Complement 77 0.456 92 0.544
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3.2 Simulated results for phase two
The phase two allocation system has the same objectives as that of phase one: bring the arms as close
together as possible in terms of the relevant prognostic factors. However, in phase two, the logistics for
allocation are different from those applied in phase one. We have now three arms and, the patients are
allocated sequentially one-by-one. In addition, the factors used for balancing in this phase are not exactly
the same. As well as now taking level of education, marital status, and sample size into consideration, the
factor history of previous treatment history, unlike in phase one, is based on the relative reduction, during
phase one, in the Y-BOCS score. Patients presenting a > 35% reduction in Y-BOCS score are not included
in this phase. To consider sample size as a factor, the proportion of patients in each group will also be
included in the distance calculation. Table 3 presents the allocation results for 90 patients selected from
among those in n1 of phase one.
Table 3. Sequential (reverse order) allocation of 90 patients in phase two: patients from phase one.
Prognostic Composition Arm 1 frequencies Arm 2 frequencies Arm 3 frequencies
factor Category Absolute Relative Absolute Relative Absolute Relative
Current A0 13 (14) 0.433 13 (12) 0.433 14 (14) 0.467
age A1 13 (12) 0.433 12 (12) 0.400 11 (12) 0.367
A2 4 (4) 0.133 5 (5) 0.167 5 (5) 0.167
OCD (L;M) 0 (1) 0.000 0 (0) 0.000 1 (0) 0.033
symptom (M;L) 0 (0) 0.000 0 (0) 0.000 0 (0) 0.000
severity (L;H) 0 (0) 0.000 0 (0) 0.000 0 (0) 0.000
(H;L) 1 (1) 0.033 0 (1) 0.000 1 (0) 0.033
(M;M) 12 (11) 0.400 14 (12) 0.467 10 (13) 0.333
(M;H) 2 (2) 0.067 2 (2) 0.067 3 (3) 0.100
(H;M) 4 (3) 0.133 3 (4) 0.100 4 (4) 0.133
(H;H) 11 (12) 0.367 11 (10) 0.367 11 (11) 0.367
Treatment h0 15 (15) 0.500 15 (15) 0.500 15 (15) 0.500
history h1 9 (10) 0.300 10 (9) 0.333 10 (10) 0.333
h2 6 (5) 0.200 5 (5) 0.167 5 (6) 0.167
Level of sc0 14 (15) 0.467 15 (14) 0.500 15 (15) 0.500
education sc1 0 (0) 0.000 0 (0) 0.000 0 (0) 0.000
sc2 0 (0) 0.000 0 (0) 0.000 0 (0) 0.000
sc3 16 (15) 0.533 15 (15) 0.500 15 (16) 0.500
Marital si0 16 (15) 0.533 15 (15) 0.500 15 (16) 0.500
status si1 14 (15) 0.467 15 (14) 0.500 15 (15) 0.500
Gender M 13 (13) 0.433 13 (12) 0.433 13 (14) 0.433
F 17 (17) 0.567 17 (17) 0.567 17 (17) 0.567
Sample Arm size 30 (30) 0.333 30 (29) 0.333 30 (31) 0.333
size Complement 60 (60) 0.667 60 (61) 0.667 60 (59) 0.667
4. DISCUSSION
The objective of using this strategy of random allocation of patients in different treatment arms is to
avoid intentional bias in group selection. However, treatment group imbalance for prognostic factors can still
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occur (Pocock et al. 2002). These unfortunate results of randomisation can be prevented by using techniques
that produce, rather than random allocation, an intentional optimal allocation of patients to each treatment
arm.
Another interesting point is the choice of the Aitchison distance to treat compositional data. To illustrate
the difference between the Aitchison distance and the standard Euclidian distance, we ask the reader to
calculate the two distances for the pairs (A1;A2) and (B1;B2) of relative frequency vectors defined below:
A1 = (0.1; 0.2; 0.7), A2 = (0.2; 0.1; 0.7),
B1 = (0.2; 0.4; 0.4) and B2 = (0.4; 0.2; 0.4)
The standard Euclidian measure would produce D[A1;A2] = 0.1414 and D[B1;B2] = 0.2828. Note that
the Aitchson distance will produce, as expected for an adequate distance, the same value for both pairs:
∆[A1;A2] = ∆[B1;B2] = 0.9803. Note that, for any category j (= 1, 2, 3), the ratio between frequencies are
the same for the two pairs:
A1j
A2j
=
B1j
B2j
We also notice that there will be problems if a frequency of 0 occurs for a particular class. It is recom-
mended that prior correction be used, beginning the allocating at a small real number for each category that
should be added to the observed absolute frequency. As an analogy to Bayesian categorical data analysis, we
would take an equal constant for each category, as in the standard strategy. Our recommendation is to add
1/k to the absolute frequencies for each category, thereby avoiding the occurrence of a relative frequency of
0 in any category.
The ’random’ aspect of treatment arm selection is preserved, due to the random sequence in which pa-
tients arrive for inclusion in clinical trials. The most important property of the allocation strategy defined
here is the rationale that allows verification of the fact that the strategy was adhered to. The use of a purely
randomised strategy cannot be proved after the trial has been concluded. To ensure that the order in which
the patients enter the experiment is random, we consider the reverse order of the first 169 (90) patients in
phase one (in phase two). In Table 3, it can be seen how close the results are those obtained for the original
order. An interesting fact is illustrated in Tables 4 and 5. We can see that more than half of patients would
change arms by reversing the order in which they enter into a phase. In phase one, 90 of the 169 patients
would have changed arms if a reverse order was considered. For phase two, considering the reverse order, 48
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of the 90 patients would have changed arms.
Table 4. Phase one patient allocation.
Reverse order Sample
Original order arm 1 arm 2 size
arm 1 47 45 92
arm 2 45 32 77
Sample size 92 77 169
Table 5. Phase two patient allocation.
Reverse order Sample
Original order arm 1 arm 2 arm 2 size
arm 1 15 9 6 30
arm 2 10 11 9 30
arm 3 5 9 16 30
Sample size 30 29 31 90
This article describes a method of computer-based intentional allocation that has the advantage of being
flexible, effective, and feasible for the allocation of each consecutive patient, or group of three patients, in
terms of multiple covariates. The development of intentional allocation methods, adaptable to different study
designs, can reduce sample sizes without increasing bias. Future studies are warranted in order to determine
the possible sample size reduction and to evaluate the effectiveness of this procedure when a great number of
covariates are included. The procedure presented here is reliable for the inclusion of up to 6 compositional
covariates with 21 possible alternative results. When using this procedure, researchers should include in the
allocation strategy any variables suspected of influencing treatment response.
One limitation of the proposed procedure is the need to know the value of each prognostic factor, for
each patient entering the study, prior to allocation. Consequently, values of prognostic factors that can only
be obtained through long-term evaluations cannot be included in the model. Another issue is the weights
given to the allocation factors. For the trial in question, the first author (the psychiatrist responsible for
conducting the trial) based the choice of variable weights on the evidence levels of the prognostic factors
influencing treatment responses. Although this was an arbitrary decision, it does not favour any allocation
tendency that might result in arm imbalance, thereby favouring any particular result in terms of treatment
response.
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5. CONCLUSION
In conclusion, the procedure described here can be easily adapted to different study designs. The results
of the trial, used as illustration, show that the methodology was reliable for the sample tested. There are,
however, some reliability issues that require further investigation, such as the inclusion of cases presenting
a great number of factors or factors having a great number of possible alternative categories. Nevertheless,
we believe that this paper presents a procedure that will be useful in avoiding imbalance among treatment
arms when patient allocation is performed sequentially.
Figure 1: Clinical Trial Study Design.
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Trial registration
Clinicaltrials.gov identifier: NCT00466609
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